Beam Therapeutics (BEAM) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Tarsus Pharmaceuticals (TARS) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 7.6% versus a loss of 1.4%. Over five years, TARS leads with a +158.1% price change compared with -73.4% for BEAM. Tarsus Pharmaceuticals is the larger company by market cap ($3.44 billion vs $2.56 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | TARS |
|---|---|---|
| Share price | $24.77 | $73.61 |
| Market cap | $2.56B | $3.44B |
| 1-day change | -1.82% | -0.67% |
| YTD return | -10.64% | -10.10% |
| 1-year return | -1.43% | +7.59% |
| 5-year return | -73.41% | +158.10% |
| EPS (TTM) | $-0.68 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.26 | $91.53 |
| 52-week low | $20.23 | $53.89 |
| Distance from 52-week high | -35.26% | -19.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +110.54% | +35.17% |
| Average volume | 1.94M | 906.66K |
| Shares outstanding | 103.29M | 46.79M |
| Employees | 540 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
BEAM vs TARS FAQ
Which is bigger, Beam Therapeutics or Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.44B compared with $2.56B for Beam Therapeutics (BEAM).
Which stock has performed better over the past year, BEAM or TARS?
TARS returned +7.59% over the past 12 months, compared with -1.43% for BEAM (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.